1 | physicians and other health | | | | | | | 2 | 0.14% |
2 | treatment of disease labtech | | | | | | | 2 | 0.14% |
3 | applying the reference and | | | | | | | 2 | 0.14% |
4 | by applying the reference | | | | | | | 2 | 0.14% |
5 | laboratories by applying the | | | | | | | 2 | 0.14% |
6 | commercial laboratories by applying | | | | | | | 2 | 0.14% |
7 | standard commercial laboratories by | | | | | | | 2 | 0.14% |
8 | diagnostics differentiates itself from | | | | | | | 2 | 0.14% |
9 | identification system that uses | | | | | | | 2 | 0.14% |
10 | disease labtech diagnostics differentiates | | | | | | | 2 | 0.14% |
11 | of disease labtech diagnostics | | | | | | | 2 | 0.14% |
12 | disease disease processes or | | | | | | | 2 | 0.14% |
13 | standard method to each | | | | | | | 2 | 0.14% |
14 | monitor disease disease processes | | | | | | | 2 | 0.14% |
15 | or monitor disease disease | | | | | | | 2 | 0.14% |
16 | identify or monitor disease | | | | | | | 2 | 0.14% |
17 | to identify or monitor | | | | | | | 2 | 0.14% |
18 | tests to identify or | | | | | | | 2 | 0.14% |
19 | laboratory tests to identify | | | | | | | 2 | 0.14% |
20 | add new diagnostic clinical | | | | | | | 2 | 0.14% |
21 | continually add new diagnostic | | | | | | | 2 | 0.14% |
22 | also continually add new | | | | | | | 2 | 0.14% |
23 | the reference and gold | | | | | | | 2 | 0.14% |
24 | method to each analyte | | | | | | | 2 | 0.14% |
25 | department staff also continually | | | | | | | 2 | 0.14% |
26 | patients physicians and other | | | | | | | 2 | 0.14% |
27 | an automated mass spectrometry | | | | | | | 2 | 0.14% |
28 | direct testing by which | | | | | | | 2 | 0.14% |
29 | integration of idast results | | | | | | | 2 | 0.14% |
30 | of idast results for | | | | | | | 2 | 0.14% |
31 | idast results for optimized | | | | | | | 2 | 0.14% |
32 | results for optimized workflow | | | | | | | 2 | 0.14% |
33 | of the patient a | | | | | | | 2 | 0.14% |
34 | benefit of the patient | | | | | | | 2 | 0.14% |
35 | the benefit of the | | | | | | | 2 | 0.14% |
36 | to patients physicians and | | | | | | | 2 | 0.14% |
37 | to each analyte and | | | | | | | 2 | 0.14% |
38 | a leader in the | | | | | | | 2 | 0.14% |
39 | being a leader in | | | | | | | 2 | 0.14% |
40 | thereby being a leader | | | | | | | 2 | 0.14% |